
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma Inc is positioned attractively in the market due to its focus on cannabinoid-based formulations targeting significant medical conditions, including Alzheimer's disease, which showcases a strong potential for therapeutic advancements. The investigational drug IGC-AD1 has exhibited promising preclinical results, specifically a clinically significant reduction in agitation among Alzheimer's patients, which may lead to further positive data and subsequent stock catalysts. Additionally, the company's current valuation appears favorable, supported by updated net present value analyses indicating substantial upside potential from the prevailing share price.
Bears say
IGC Pharma reported a net loss of $0.7 million, leading to an earnings per share (EPS) of $(0.01), which fell short of both the company's and the consensus estimates of $(0.02). The company anticipates revenue of $0.2 million, below the consensus estimate of $0.3 million, indicating potential challenges in generating adequate sales. Furthermore, the outlook is marred by numerous risks, including liquidity concerns, the uncertain efficacy and safety of product candidates in clinical trials, regulatory approval hurdles, and market competition, all of which could significantly hinder the company's financial performance.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares